S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
NASDAQ:MORF

Morphic (MORF) Stock Price, News & Analysis

$35.30
-0.55 (-1.53%)
(As of 02/23/2024 ET)
Today's Range
$34.47
$36.07
50-Day Range
$26.64
$40.31
52-Week Range
$19.34
$63.08
Volume
302,336 shs
Average Volume
615,133 shs
Market Capitalization
$1.76 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$59.75

Morphic MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
69.3% Upside
$59.75 Price Target
Short Interest
Bearish
12.12% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.57
Upright™ Environmental Score
News Sentiment
0.55mentions of Morphic in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$986,231 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.42) to ($3.85) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.01 out of 5 stars

Medical Sector

193rd out of 939 stocks

Pharmaceutical Preparations Industry

82nd out of 437 stocks


MORF stock logo

About Morphic Stock (NASDAQ:MORF)

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. The company was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

MORF Stock Price History

MORF Stock News Headlines

HUGE BUY ALERT: Move Fast, Musk…
Since 2018, Eric Wade's investment recommendations have averaged 115%. But one investment he just discovered in Phoenix could blow them all away. It involves Elon Musk, Bill Gates, 32 government mandates, and an AI breakthrough... Not to mention a technology that could help you earn $30,000 a year outside the stock market. 
Recap: Morphic Holding Q4 Earnings
New Strong Buy Stocks for February 14th
HUGE BUY ALERT: Move Fast, Musk…
Since 2018, Eric Wade's investment recommendations have averaged 115%. But one investment he just discovered in Phoenix could blow them all away. It involves Elon Musk, Bill Gates, 32 government mandates, and an AI breakthrough... Not to mention a technology that could help you earn $30,000 a year outside the stock market. 
Morphic initiated with bullish view at Citi, here's why
Morphic to Present at November Investor Conferences
See More Headlines
Receive MORF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Morphic and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
2/23/2024
Next Earnings (Estimated)
4/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MORF
Fax
N/A
Employees
115
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$59.75
High Stock Price Target
$80.00
Low Stock Price Target
$33.00
Potential Upside/Downside
+69.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

Net Income
$-59,040,000.00
Pretax Margin
-2,034.98%

Debt

Sales & Book Value

Annual Sales
$70.81 million
Book Value
$9.06 per share

Miscellaneous

Free Float
35,765,000
Market Cap
$1.76 billion
Optionable
Optionable
Beta
1.41
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Bruce N. Rogers Ph.D. (Age 55)
    President & Interim Principal Executive Officer
    Comp: $787.88k
  • Dr. Timothy A. Springer Ph.D. (Age 76)
    Founder, Independent Director & Member of Scientific Advisory Board
    Comp: $40k
  • Dr. Marc Schegerin M.B.A. (Age 48)
    M.D., CFO & COO
    Comp: $722.38k
  • Dr. Praveen P. Tipirneni M.D. (Age 56)
    CEO, MD & Director (Leave of Absence)
    Comp: $991.33k
  • Mr. Robert E. Farrell Jr.Mr. Robert E. Farrell Jr. (Age 59)
    CPA, Senior VP of Finance & Chief Accounting Officer
  • Dr. Blaise Lippa Ph.D.
    Chief Scientific Officer
  • Mr. William D. DeVaul Esq. (Age 53)
    General Counsel & Secretary
    Comp: $601.44k
  • Mr. Aaron Pelta
    Senior Vice President of Business & Corporate Development
  • Ms. Joanne Gibbons
    Senior Vice President of Regulatory Affairs














MORF Stock Analysis - Frequently Asked Questions

Should I buy or sell Morphic stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Morphic in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MORF shares.
View MORF analyst ratings
or view top-rated stocks.

What is Morphic's stock price target for 2024?

7 Wall Street analysts have issued 1 year price objectives for Morphic's stock. Their MORF share price targets range from $33.00 to $80.00. On average, they anticipate the company's share price to reach $59.75 in the next twelve months. This suggests a possible upside of 69.3% from the stock's current price.
View analysts price targets for MORF
or view top-rated stocks among Wall Street analysts.

How have MORF shares performed in 2024?

Morphic's stock was trading at $28.88 at the beginning of the year. Since then, MORF stock has increased by 22.2% and is now trading at $35.30.
View the best growth stocks for 2024 here
.

When is Morphic's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 23rd 2024.
View our MORF earnings forecast
.

How were Morphic's earnings last quarter?

Morphic Holding, Inc. (NASDAQ:MORF) announced its quarterly earnings results on Thursday, November, 4th. The company reported ($0.69) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.04. The firm had revenue of $3.10 million for the quarter, compared to the consensus estimate of $5.19 million. The business's revenue for the quarter was down 88.0% compared to the same quarter last year.

What other stocks do shareholders of Morphic own?
When did Morphic IPO?

(MORF) raised $75 million in an IPO on Thursday, June 27th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Cowen, BMO Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO.

Who are Morphic's major shareholders?

Morphic's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Point72 Asset Management L.P. (9.23%), Vanguard Group Inc. (4.67%), Price T Rowe Associates Inc. MD (4.47%), Price T Rowe Associates Inc. MD (4.47%), Federated Hermes Inc. (2.01%) and Goldman Sachs Group Inc. (1.28%). Insiders that own company stock include Amir Nashat, Bruce Rogers, Fund V Gp LP Omega, Fund V LP Omega, Joseph P Slattery, Marc Schegerin, Peter Linde, Praveen P Tipirneni, Robert E Farrell Jr, Robert E Farrell, Jr, Timothy A Springer, Timothy A Springer and William Devaul.
View institutional ownership trends
.

How do I buy shares of Morphic?

Shares of MORF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MORF) was last updated on 2/23/2024 by MarketBeat.com Staff